Cancer Research Cell Death Mechanisms and Cancer Therapy  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seki, Y.
Right arrow Articles by Kai, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seki, Y.
Right arrow Articles by Kai, H.
[Cancer Research 62, 6579-6586, November 15, 2002]
© 2002 American Association for Cancer Research


Molecular Biology and Genetics

The ETS Transcription Factor MEF Is a Candidate Tumor Suppressor Gene on the X Chromosome1

Yoshiyuki Seki, Mary Ann Suico, Ayako Uto, Akinobu Hisatsune, Tsuyoshi Shuto, Yoichiro Isohama and Hirofumi Kai2

Departments of Molecular Medicine [Y. S., M. A. S., T. S., H. K.] and Pharmacological Sciences [Y. S., M. A. S., A. U., A. H., Y. I.], Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan

Although X chromosome transfer experiments indicated that tumor suppressor genes are present on the X chromosome, they have not been previously identified. In this report, we show that the ETS transcription factor MEF (ELF4), which is located on chromosome Xq26.1, possesses tumor suppressive capability. MEF expression was up-regulated by 5-azacytidine in some cancer cell lines. MEF overexpression induced morphological changes, such as the conversion of normally loose cell-cell contacts to strong interactions similar to those seen in the presence of matrix metalloproteinase (MMP) inhibitor BB94. In the colony formation assay, A549 cells, but not MEF-overexpressing cells, formed colonies in soft agar culture. Furthermore, MEF-overexpressing cells s.c. injected in the nude mice did not grow, whereas the control cells did. The A549 tumors were poorly differentiated, whereas the MEF-overexpressing tumors were well differentiated. By immunostaining with CD31, a marker on vascular endothelial cells, we found that tumor angiogenesis was significantly suppressed in the tumors formed from MEF-overexpressing cells. In addition, the conditioned media from A549 cell cultures stimulated the migration of human umbilical vein endothelial cells, whereas conditioned media from MEF-overexpressing cell cultures had less of an effect. By gelatin zymography, Western blotting analysis, and immunohistochemistry, we found that the expression levels of MMP-9 and MMP-2 were significantly reduced in MEF-overexpressing tumors. Immunohistochemical analyses showed that interleukin (IL)-8 expression was reduced in the MEF-overexpressing tumors in nude mice. Furthermore, IL-8 mRNA expression in vitro was significantly down-regulated in MEF-overexpressing cells, compared with A549 cells. MEF suppressed the transcription and promoter activities of the genes encoding MMP-9 and IL-8, whereas ETS-2 up-regulated these activities. Therefore, we propose that MEF is a candidate tumor suppressor gene on the X chromosome with activities that are opposite to those of ETS-2.




This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
G. Sashida, Y. Liu, S. Elf, Y. Miyata, K. Ohyashiki, M. Izumi, S. Menendez, and S. D. Nimer
ELF4/MEF Activates MDM2 Expression and Blocks Oncogene-Induced p16 Activation To Promote Transformation
Mol. Cell. Biol., July 1, 2009; 29(13): 3687 - 3699.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. Taura, A. Eguma, M. A. Suico, T. Shuto, T. Koga, K. Komatsu, T. Komune, T. Sato, H. Saya, J.-D. Li, et al.
p53 Regulates Toll-Like Receptor 3 Expression and Function in Human Epithelial Cell Lines
Mol. Cell. Biol., November 1, 2008; 28(21): 6557 - 6567.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
T. Hirai, R. Murakami, H. Nakamura, M. Kitajima, H. Fukuoka, A. Sasao, M. Akter, Y. Hayashida, R. Toya, N. Oya, et al.
Prognostic Value of Perfusion MR Imaging of High-Grade Astrocytomas: Long-Term Follow-Up Study
AJNR Am. J. Neuroradiol., September 1, 2008; 29(8): 1505 - 1510.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. A. Suico, H. Yoshida, Y. Seki, T. Uchikawa, Z. Lu, T. Shuto, K. Matsuzaki, M. Nakao, J.-D. Li, and H. Kai
Myeloid Elf-1-like Factor, an ETS Transcription Factor, Up-regulates Lysozyme Transcription in Epithelial Cells through Interaction with Promyelocytic Leukemia Protein
J. Biol. Chem., April 30, 2004; 279(18): 19091 - 19098.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. V. Hedvat, J. Yao, R. A. Sokolic, and S. D. Nimer
Myeloid ELF1-like Factor Is a Potent Activator of Interleukin-8 Expression in Hematopoietic Cells
J. Biol. Chem., February 20, 2004; 279(8): 6395 - 6400.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
R. Hosokawa, K. Nonaka, M. Morifuji, L. Shum, and M. Ohishi
TGF-{beta}3 Decreases Type I Collagen and Scarring after Labioplasty
Journal of Dental Research, July 1, 2003; 82(7): 558 - 564.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.